{
 "drug": "Crinecerfont Capsule",
 "asOf": "2026-08-25",
 "status": "discontinuing",
 "since": "04/28/2026",
 "dayN": 119,
 "cat": "Endocrinology/Metabolism",
 "companies": [
  "Neurocrine Biosciences, Inc."
 ],
 "reasons": [],
 "records": [
  {
   "discontinued_date": "04/28/2026",
   "update_type": "New",
   "initial_posting_date": "04/28/2026",
   "package_ndc": "70370-5025-1",
   "generic_name": "Crinecerfont Capsule",
   "contact_info": "858-617-7600",
   "related_info": "Neurocrine is discontinuing only the 25 mg soft gel capsule dose strength (NDC 70370-5025-01). The 50mg and 100mg soft gel capsule dose strength (NDC 70370-5050-1 and 70370-5100-1), and 50 mg/mL oral solution will continue to be marketed (NDC 70370-5250-1).",
   "update_date": "04/28/2026",
   "therapeutic_category": [
    "Endocrinology/Metabolism"
   ],
   "dosage_form": "Capsule",
   "presentation": "Crenessity, Capsule, 25 mg (NDC 70370-5025-1)",
   "company_name": "Neurocrine Biosciences, Inc.",
   "status": "To Be Discontinued"
  }
 ]
}